Blueprint Medicines Corporation (BPMC) Director Daniel Lynch Sells 5,000 Shares

Blueprint Medicines Corporation (NASDAQ:BPMC) Director Daniel Lynch sold 5,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $63.38, for a total value of $316,900.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Daniel Lynch also recently made the following trade(s):

  • On Monday, September 18th, Daniel Lynch sold 2,500 shares of Blueprint Medicines Corporation stock. The stock was sold at an average price of $60.00, for a total value of $150,000.00.

Shares of Blueprint Medicines Corporation (NASDAQ BPMC) traded down $0.57 during trading on Friday, hitting $66.17. The stock had a trading volume of 281,027 shares, compared to its average volume of 366,571. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. Blueprint Medicines Corporation has a 12-month low of $25.08 and a 12-month high of $74.42.

Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.06). The firm had revenue of $8.07 million for the quarter, compared to the consensus estimate of $5.35 million. Blueprint Medicines Corporation had a negative net margin of 437.83% and a negative return on equity of 43.11%. Blueprint Medicines Corporation’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.62) earnings per share. research analysts forecast that Blueprint Medicines Corporation will post -3.74 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/11/18/blueprint-medicines-corporation-bpmc-director-daniel-lynch-sells-5000-shares.html.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rockefeller Financial Services Inc. bought a new position in Blueprint Medicines Corporation during the 3rd quarter worth approximately $160,000. Turner Investments LLC bought a new position in Blueprint Medicines Corporation during the 3rd quarter worth approximately $209,000. Great West Life Assurance Co. Can grew its position in Blueprint Medicines Corporation by 53.6% during the 3rd quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 1,163 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in Blueprint Medicines Corporation by 68.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 1,391 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Blueprint Medicines Corporation during the 3rd quarter worth approximately $244,000. Institutional investors and hedge funds own 90.83% of the company’s stock.

A number of brokerages recently issued reports on BPMC. Wedbush reissued an “outperform” rating and set a $82.00 price objective (up previously from $70.00) on shares of Blueprint Medicines Corporation in a report on Monday, November 6th. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corporation in a report on Tuesday, October 31st. BTIG Research began coverage on Blueprint Medicines Corporation in a report on Friday, September 29th. They issued a “buy” rating and a $90.00 price target on the stock. DA Davidson began coverage on Blueprint Medicines Corporation in a report on Friday, September 29th. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $80.00 price target (up previously from $66.00) on shares of Blueprint Medicines Corporation in a report on Wednesday, November 1st. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $70.47.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply